Mortality Rate Much Higher in COVID-19 Patients Consuming Hydroxychloroquine! WHO Pauses Clinical Trial

New Delhi : A recent research report published in The Lancet analyzed data from 15,000 patients of COVID-19 who were given either chloroquine or its analogue hydroxychloroquine. The authors of this report claim that mortality is much higher in COVID-19 patients consuming hydroxychloroquine, alone or with macrolides.

The World Health Organization (WHO) has temporarily banned testing of hydroxychloroquine for COVID-19 treatment over safety issues. WHO Director General, Dr. Tedros Adhanom Ghebreyesus said that the WHO working group has decided to temporarily stop the solidarity test on COVID-19 patients with hydroxychloroquine and its data will be reviewed by the Data Safety Monitoring Board.

It is noteworthy that US President Donald Trump himself is advocating the use of hydroxychloroquine for the treatment of COVID-19. He has even stated that he himself is using hydroxychloroquine to avoid the coronavirus.

"The review will consider data collected so far in the Solidarity Trial and, in particular robust randomised available data, to adequately evaluate the potential benefits and harms from this drug"-@DrTedros #COVID19

— World Health Organization (WHO) (@WHO) May 25, 2020

According to Large Observational Study, treatment with the anti-malaria drug hydroxychloroquine for COVID-19, with or without the antibiotic azithromycin, does not benefit COVID-19 patients.